1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Vivos Inc.

Vivos Inc.

RDGL
Vivos Inc.US flagOther OTC
0.05
USD
+0.00
- -
24.89MMarket Cap
Vivos Inc.
RDGL
(Other OTC)

Recent

price

0.05

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
5.14
4.54
2.62
1.12
0.06
0.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-57.75
-31.72
-90.77
-27.58
-45.38
2.69
-3.67
-1.06
-0.14
-0.01
- -
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
Basic EPS, GAAP
-9.55
-11.03
-20
-16.24
-2.85
-0.52
-0.72
-0.21
-0.01
- -
- -
- -
- -
- -
- -
- -
-0.01
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-34.92
-54.76
-96.64
-59.37
-9.46
-7.59
-0.76
-0.52
-0.01
-0.01
- -
- -
- -
- -
- -
- -
0.01
Book Value per Share
-37.7
-58.46
-100.33
-59.65
-9.48
-7.61
-0.76
-0.52
-0.01
-0.01
- -
- -
- -
- -
- -
- -
0.01
Tangible Book Value per Share
- -
- -
- -
- -
- -
2
3
6
56
175
223
326
351
369
410
453
469
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
-991.46
-650.88
-2,367.52
-2,545.9
-8,109.43
-8,467.16
-54,458.07
-64,551.41
- -
-13,999.78
-9,607.44
-16,805.25
-6,898.13
-14,323.83
-9,303.03
-4,628.68
-2,852.46
Operating Margin (%)
1
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-4
-3
-9
-3
-18
6
-10
-6
-8
-2
-1
-3
-2
-3
-3
-3
-4
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-1,124.48
-698.58
-3,462.65
-2,468.52
-75,114.92
25,853.19
-121,545.33
-158,330.71
- -
-16,948.39
-13,671.31
-16,979.69
-6,767.75
-14,844.89
-10,396.31
-4,483.86
-3,633.58
Profit Margin (%)
-3
-5
-11
-9
-20
-10
-3
-4
-1
-1
- -
1
2
1
2
2
2
Working Capital
1
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
-3
-5
-10
-9
-20
-14
-3
-4
-1
-1
- -
1
2
1
2
2
3
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
-71.55
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-338.44
-158.19
-191.65
-165.97
-161.23
-132.63
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
455
483
494
Market Capitalization
31
43
30

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
2
3
2
Cash, Cash Equivalents & STI
2
3
2
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
- -
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
434.99%
902.14%
-22.65%
Free Cash Flow
10.71%
20.05%
28.32%
Net Income, GAAP
-20.77%
36.99%
5.35%
Sales/Revenue/Turnover
- -
79.82%
144.25%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
-0.01
2025
- -
- -
- -
- -
-0.01
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Outset Medical, Inc. (OM)
Heart Tronics, Inc. (HRTT)
Episurf Medical AB (EPIS-B.ST)
Modern Dental Group Limited (3600.HK)
Hyperfine, Inc. (HYPR)
Demant A/S (WILYY)
Business
I did not find relevant search results specifically about Vivos Inc. (Ticker: RDGL) or its latest major company changes based on the initial general queries about company name changes and business descriptions. I will perform a more focused targeted search on Vivos Inc. to gather accurate and up-to-date information regarding its products, services, recent changes, and other relevant details.

Company News

Company News APIChatGPT

  • globenewswire.com

    Vivos Inc. Announces Peer-Reviewed Publication Characterizing PrecisionGel™ Polymer Platform in Elsevier Journal of Drug Delivery Science and Technology

  • newsfilecorp.com

    Vivos Therapeutics to Present at the 2026 Moody Capital Solutions Disruptive Growth & Life Sciences Conference

  • globenewswire.com

    Vivos Therapeutics and South Palm Cardiovascular Associates Sign Definitive Agreements to Launch Regional Sleep Testing and Treatment Center

  • globenewswire.com

    Vivos Therapeutics Reports Record New Patient Referrals at its Nevada Sleep & Airway Medicine Centers

  • globenewswire.com

    Vivos Therapeutics Opens New Sleep Testing and Treatment Facility in Nevada to Meet Rapidly Growing Patient Demand for Sleep Apnea Testing and Treatment

  • globenewswire.com

    Vivos Inc. Achieves Two Major Operational Milestones: First IsoPet® Shipments from New U.S. Production Facility and Authorization from India's Nuclear Regulatory Authority for International Manufacturing Center

  • globenewswire.com

    Vivos Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Update

  • globenewswire.com

    Vivos Therapeutics Schedules Release of Second Quarter 2026 Financial Results and Conference Call

  • globenewswire.com

    Vivos Therapeutics Announces Issuance of New US Patent Broadening Protection for Its Vivos CARE Oral Medical Device Technology

  • globenewswire.com

    Vivos Inc. (OTCQB: RDGL) Reports Second Quarter 2026 Progress and Corporate Update - Correction

  • globenewswire.com

    Vivos Inc. (OTCQB: RDGL) Reports Second Quarter 2026 Progress and Corporate Update - Correction

  • globenewswire.com

    Vivos Inc. (OTCQB: RDGL) Reports Second Quarter 2026 Progress and Corporate Update

  • globenewswire.com

    Vivos Inc. (OTCQB: RDGL) Receives U.S. FDA Approval for Investigational Device Exemption (IDE) to Initiate Human Clinical Feasibility Study for RadioGel® Precision Radionuclide Therapy™

  • globenewswire.com

    Vivos Inc. (OTCQB: RDGL) Receives U.S. FDA Approval for Investigational Device Exemption (IDE) to Initiate Human Clinical Feasibility Study for RadioGel® Precision Radionuclide Therapy™

  • globenewswire.com

    Vivos' Vida® Appliance Shows Statistically Significant Improvement in Insomnia Severity in 100% of Study Participants

  • globenewswire.com

    Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity

  • globenewswire.com

    Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering

  • globenewswire.com

    Vivos Inc. Announces Receipt of Washington State Radioactive Materials License for IsoPet® Manufacturing

  • globenewswire.com

    Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients

  • globenewswire.com

    Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026